क्लैरिथ्रोमाइसिन और लैपाटिनिब का इंटरैक्शन

Avoid strong CYP3A4 inhibitors.

If unavoidable, consider dose reduction of TYKERB in patients coadministered a strong CYP3A4 inhibitor.

TYKERB may prolong the QT interval in some patients.

Ketoconazole : In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.

Effects of Lapatinib on Drug-Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4, CYP2C8, and P-glycoprotein (P-gp, ABCB1) in vitro at clinically relevant concentrations and is a weak inhibitor of CYP3A4 in vivo.